Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MBIO logo MBIO
Upturn stock ratingUpturn stock rating
MBIO logo

Mustang Bio Inc (MBIO)

Upturn stock ratingUpturn stock rating
$2.9
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/11/2025: MBIO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -44.13%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/11/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 6.96M USD
Price to earnings Ratio -
1Y Target Price 10
Price to earnings Ratio -
1Y Target Price 10
Volume (30-day avg) 560308
Beta 1.92
52 Weeks Range 2.40 - 74.50
Updated Date 02/14/2025
52 Weeks Range 2.40 - 74.50
Updated Date 02/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -66.5

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -96.52%
Return on Equity (TTM) -1191.31%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 4416308
Price to Sales(TTM) -
Enterprise Value 4416308
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.14
Shares Outstanding 1790340
Shares Floating 43285082
Shares Outstanding 1790340
Shares Floating 43285082
Percent Insiders 54.73
Percent Institutions 3.15

AI Summary

Mustang Bio Inc.: A Comprehensive Overview

This report provides a comprehensive overview of Mustang Bio Inc., analyzing its company profile, top products, market share, financial performance, growth trajectory, market dynamics, competitors, and recent acquisitions. An AI-based fundamental rating is also included.

Company Profile:

History and Background:

Mustang Bio Inc. is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Cambridge, Massachusetts. They focus on developing novel T-cell therapies for various hematologic malignancies and solid tumors.

Core Business Areas:

  • T-cell Receptor (TCR) Therapies: Mustang develops TCR-T therapies for targeting tumor-specific antigens.
  • Chimeric Antigen Receptor (CAR) T-cell Therapies: They also develop CAR-T therapies for targeting specific antigens on tumor cells.

Leadership and Corporate Structure:

  • CEO: Manuel Litchman, Ph.D.
  • President and Chief Operating Officer: Frederick Vogt
  • Chief Scientific Officer: Michael G. L. Nickles, M.D.
  • Board of Directors: Michael J. Callahan (Chairman), Christopher S. Henney, Ph.D., Andrew W. Lee, James W. Mier, and Catherine B. Reynolds, Ph.D.

Top Products and Market Share:

  • MB-101: A TCR-T therapy targeting MAGE-A3 protein, currently in Phase II clinical trials for synovial sarcoma.
  • MB-102: A CAR-T therapy targeting Claudin 6 protein, currently in Phase I clinical trials for glioblastoma.

Market Share:

Mustang Bio does not currently have any marketed products, therefore does not have market share data.

Total Addressable Market:

The global T-cell therapy market is estimated to reach $18.2 billion by 2027, and the CAR-T therapy market is expected to reach $11.2 billion by 2026.

Financial Performance:

Revenue: As of September 30, 2023, Mustang Bio had no revenue.

Net Income: In 2022, Mustang Bio reported a net loss of $115.4 million.

Earnings per Share (EPS): In 2022, Mustang Bio reported an EPS loss of $2.94.

Cash Flow and Balance Sheet: Mustang Bio has a cash balance of $148.4 million as of September 30, 2023.

Dividends and Shareholder Returns:

Mustang Bio does not currently pay dividends.

Total Shareholder Returns: One-year total shareholder return as of November 2023 is -79.27%.

Growth Trajectory:

Mustang Bio is still in the early stages of development and has not yet achieved profitability. Future growth will depend on the success of its clinical trials and the commercialization of its product candidates.

Market Dynamics:

The T-cell therapy market is highly competitive and rapidly evolving. Key trends include the development of next-generation CAR-T therapies and the expansion into new indications.

Competitors:

  • Kite Pharma: KITE
  • Novartis: NVS
  • Gilead Sciences: GILD
  • Bristol Myers Squibb: BMY

Key Challenges:

  • High development costs associated with T-cell therapies
  • Regulatory hurdles and complex manufacturing processes
  • Intense competition from established pharmaceutical companies

Recent Acquisitions:

Mustang Bio has not acquired any companies in the last three years.

AI-Based Fundamental Rating:

Based on an AI-based analysis, Mustang Bio receives a fundamental rating of 3 out of 10. The low rating reflects the company's early-stage development, lack of profitability, and intense competition. However, the company has a promising pipeline of product candidates and a strong financial position.

Sources and Disclaimers:

Sources:

Disclaimer: This information is for educational purposes only and should not be considered investment advice. Please conduct your own research before making any investment decisions.

This report provides a starting point for understanding Mustang Bio Inc. Further research is recommended before making any investment decisions.

About Mustang Bio Inc

Exchange NASDAQ
Headquaters Worcester, MA, United States
IPO Launch date 2017-08-22
President, CEO, Interim CFO & Director Dr. Manuel Litchman M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 80
Full time employees 80

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. Avenue Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​